These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. VLDL (Very-Low-Density Lipoprotein)-Apo E (Apolipoprotein E) May Influence Lp(a) (Lipoprotein [a]) Synthesis or Assembly. Croyal M; Blanchard V; Ouguerram K; Chétiveaux M; Cabioch L; Moyon T; Billon-Crossouard S; Aguesse A; Bernardeau K; Le May C; Flet L; Lambert G; Hadjadj S; Cariou B; Krempf M; Nobécourt-Dupuy E Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):819-829. PubMed ID: 32078365 [TBL] [Abstract][Full Text] [Related]
6. Effect of the PCSK9 R46L genetic variant on plasma insulin and glucose levels, risk of diabetes mellitus and cardiovascular disease: A meta-analysis. Liu S; Wan J; Wang D; Yang Y; Fang J; Luo T; Liang D; Hu J; Hou J; Wang P Nutr Metab Cardiovasc Dis; 2024 Jun; 34(6):1339-1351. PubMed ID: 38734541 [TBL] [Abstract][Full Text] [Related]
7. The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response. Ooi TC; Krysa JA; Chaker S; Abujrad H; Mayne J; Henry K; Cousins M; Raymond A; Favreau C; Taljaard M; Chrétien M; Mbikay M; Proctor SD; Vine DF J Clin Endocrinol Metab; 2017 Sep; 102(9):3452-3460. PubMed ID: 28673045 [TBL] [Abstract][Full Text] [Related]
8. Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes. Strøm TB; Holla ØL; Cameron J; Berge KE; Leren TP Clin Chim Acta; 2010 Feb; 411(3-4):229-33. PubMed ID: 19917273 [TBL] [Abstract][Full Text] [Related]
9. Circulating PCSK9 levels are positively correlated with NMR-assessed atherogenic dyslipidaemia in patients with high cardiovascular risk. Guardiola M; Plana N; Ibarretxe D; Cabré A; González M; Ribalta J; Masana L Clin Sci (Lond); 2015 Jun; 128(12):877-82. PubMed ID: 25649668 [TBL] [Abstract][Full Text] [Related]
10. Plasma proprotein convertase subtilisin-kexin type 9 is predominantly related to intermediate density lipoproteins. Kwakernaak AJ; Lambert G; Dullaart RP Clin Biochem; 2014 May; 47(7-8):679-82. PubMed ID: 24680982 [TBL] [Abstract][Full Text] [Related]
11. An in-depth analysis shows a hidden atherogenic lipoprotein profile in non-diabetic chronic kidney disease patients. Bermudez-Lopez M; Forne C; Amigo N; Bozic M; Arroyo D; Bretones T; Alonso N; Cambray S; Del Pino MD; Mauricio D; Gorriz JL; Fernandez E; Valdivielso JM Expert Opin Ther Targets; 2019 Jul; 23(7):619-630. PubMed ID: 31100024 [No Abstract] [Full Text] [Related]
12. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia. Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088 [TBL] [Abstract][Full Text] [Related]
13. Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9. Constantinides A; Kappelle PJ; Lambert G; Dullaart RP Arch Med Res; 2012 Jan; 43(1):11-4. PubMed ID: 22300679 [TBL] [Abstract][Full Text] [Related]
14. NMR-based lipoprotein analysis for patients with severe hypercholesterolemia undergoing lipoprotein apheresis or PCSK9-inhibitor therapy (NAPALI-Study). Schettler VJ; Muellendorff F; Schettler E; Platzer C; Norkauer S; Julius U; Neumann CL Ther Apher Dial; 2019 Oct; 23(5):467-473. PubMed ID: 30663261 [TBL] [Abstract][Full Text] [Related]
15. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia. Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942 [TBL] [Abstract][Full Text] [Related]
16. Plasma PCSK9 levels and lipoprotein distribution are preserved in carriers of genetic HDL disorders. Ruscica M; Simonelli S; Botta M; Ossoli A; Lupo MG; Magni P; Corsini A; Arca M; Pisciotta L; Veglia F; Franceschini G; Ferri N; Calabresi L Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Sep; 1863(9):991-997. PubMed ID: 29852278 [TBL] [Abstract][Full Text] [Related]
17. The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis. Bonnefond A; Yengo L; Le May C; Fumeron F; Marre M; Balkau B; Charpentier G; Franc S; Froguel P; Cariou B; Diabetologia; 2015 Sep; 58(9):2051-5. PubMed ID: 26049403 [TBL] [Abstract][Full Text] [Related]
18. Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients. Chan DC; Hamilton SJ; Rye KA; Chew GT; Jenkins AJ; Lambert G; Watts GF Diabetes Obes Metab; 2010 Sep; 12(9):752-6. PubMed ID: 20649626 [TBL] [Abstract][Full Text] [Related]
19. Effect of an siRNA Therapeutic Targeting PCSK9 on Atherogenic Lipoproteins: Prespecified Secondary End Points in ORION 1. Ray KK; Stoekenbroek RM; Kallend D; Leiter LA; Landmesser U; Wright RS; Wijngaard P; Kastelein JJP Circulation; 2018 Sep; 138(13):1304-1316. PubMed ID: 29735484 [TBL] [Abstract][Full Text] [Related]